Association between neutrophil-to-high-density lipoprotein-cholesterol ratio and prevalence and mortality of diabetes: a cross-sectional study

中性粒细胞与高密度脂蛋白胆固醇比值与糖尿病患病率和死亡率的关系:一项横断面研究

阅读:1

Abstract

BACKGROUND: Inflammatory responses and lipid metabolism play critical roles in diabetes development. This study explored the association between the neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) and diabetes prevalence and mortality. METHODS: This cross-sectional study was conducted in the National Health and Nutrition Survey (NHANES) from 1999 to 2018. The correlation between NHR and the prevalence of diabetes was evaluated using logistic regression models. Additionally, the Cox proportional hazards model was applied to investigate whether NHR related to the risk of mortality from all causes and cardiovascular diseases. A series of sensitivity analyses and subgroup analyses were performed to test the robustness of the findings. RESULTS: Among the 52,428 study participants, 8,114 (15.48%) had diabetes, with a mean neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) of 3.49. In the full-adjusted model, each unit increase in NHR was related to a 17.0% higher risk of diabetes (odds ratio, 1.17 [95% CI 1.13-1.21], P < 0.001). Results were similar when participants were categorized by NHR tertiles (odds ratio, 2.08 [95% CI 1.76-2.47], comparing extreme quartiles). The stratified analyses showed that the association between NHR and risk of diabetes was more obvious in female, White, former smokers and participants with age ≥ 50 years. After a median (interquartile range) follow-up of 9.42 (5.08-14.33) years, higher NHR levels were positively associated with the risk of all-cause and cardiovascular disease mortality in diabetes patients. A series of sensitivity analyses confirmed the robustness of the findings. CONCLUSION: Elevated NHR is linked to higher diabetes prevalence and increased mortality risk in a U.S. population, independent of traditional risk factors. Regular monitoring of NHR may serve as an easy-to-measure tool for risk stratification for diabetes and its adverse outcomes. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。